LRP6 and plasma cell myeloma: This protection was demonstrated in both femurs and L4 lumbar vertebrae as illustrated in Fig. S3; and this protection in the myeloma setting has been shown elsewhere.(22, 23) Trabecular BV/TV and Tb.N parameters were almost doubled in naïve mice treated with the anti‐LRP6/DKK1 antibody combination compared to their controls who received the anti‐LRP6/DKK1 isotype combination strategy (Fig. S4Ai,ii, p < 0.001 for both).